Volpara’s online community of users has reached the milestone of 1000 members
LYNNWOOD, Wash., March 15, 2024 /PRNewswire/ — Volpara Health Technologies Ltd. (ASX: VHT), a global leader in cancer early detection and prevention software, will showcase its latest software advancements for breast centers at the National Consortium of Breast Centers (NCBC) 2024 conference, From March 15 to 19 in Las Vegas. Volpara will feature Lunit’s INSIGHT™ AI software for early cancer detection alongside the company’s suite of solutions for breast density assessment, cancer risk assessment and mammography quality.
“NCBC comes at a time of great change for breast centers with new standards from the National Accreditation Program for Breast Centers (NAPBC), a national mandate to inform density and growing clinical demands combined with staff shortages,” he says Terry Thomas, director of Volpar. “Success in this new era will require programs that embrace AI-powered solutions to automate, optimize and personalize care for providers and patients to thrive. Finding an AI partner you can trust has never been more important.”
Volpara and Lunit join forces
Volpara previously announced that it had entered into an Agreement on the implementation of the scheme with Lunit®. If the scheme is approved by Volpara shareholders and ultimately implemented, it is expected to be completed in the second quarter of 2024. Regardless of the outcome of the scheme, the distribution agreement allows Volpara to sell Lunit’s products immediately and offer a comprehensive package that uses AI to improve the mammography journey from screening until the diagnosis.
A successful Volpara customer community
Members of Volpara’s Hive, the exclusive digital community for Volpara Health users, will also gather at NCBC to discuss the latest AI research for breast centers. The Hive recently surpassed 1,000 members from various health systems, imaging groups, and breast centers, connecting online with peers and Volpar experts to share knowledge, access resources, and disseminate best practices.
Singing River deals with health differences with Volpar
Tami Hudson, RNBSN, BHCN, CGRA, Breast Health Navigator, at Singing River Health System will present during the NCBC Clinical Post-Conference: Complexities of High-Risk Breast Care on Tuesday, March 19.
Hudson’s presentation will consider the clinical impact of standardizing cancer risk assessment for every mammogram patient at four breast centers. The health system is in a state that often ranks low in health outcomes and health literacy.
Singing River Health System has used Volpara® Risk Pathways® cancer risk assessment software to identify patients at increased risk who are eligible for breast MRI or genetic testing for the past three years.
“Our comprehensive approach to care includes early identification and tailored support for high-risk patients. Genetic testing is a key tool for us,” said Hudson. “Volpara Risk Pathways guides the entire process, helping patients get the care they need to prevent cancer.”
To see the latest breast center software advancements from Volpara, visit booth #303 at NCBC 2024.
About Volpara Health (ASX: VHT)
Volpara Health makes software to save families from cancer. Health care providers use Volpara to better understand cancer risk, empower patients to make personal care decisions, and make recommendations about additional imaging, genetic testing, and other interventions. Our AI image analysis enables radiologists to precisely quantify breast tissue and helps technologists create mammograms with optimal image quality, positioning, compression and dose. In an industry facing increasing staff shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.
Volpara is a preferred partner of leading healthcare institutions worldwide. Our software is used by more than 5,600 technologists in more than 2,000 facilities, impacting nearly 17 million patients worldwide. It helps providers conduct more than three million cancer risk assessments each year and can be deployed standalone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware and genetic labs. Volpara holds the most stringent safety certifications and numerous patents and regulatory registrations, including FDA approval and CE marking. Since listing on the ASX in April 2016Society raised 132 million Australian dollars. With an office in SeattleVolpara is based in WellingtonNew Zealand.
For more information, visit www.volparahealth.com.
SOURCE Volpara Health, Inc.
